Cargando…

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

The newly identified 2019 novel coronavirus (2019-nCoV) has caused more than 11,900 laboratory-confirmed human infections, including 259 deaths, posing a serious threat to human health. Currently, however, there is no specific antiviral treatment or vaccine. Considering the relatively high identity...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tian, Xiaolong, Li, Cheng, Huang, Ailing, Xia, Shuai, Lu, Sicong, Shi, Zhengli, Lu, Lu, Jiang, Shibo, Yang, Zhenlin, Wu, Yanling, Ying, Tianlei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7048180/ https://www.ncbi.nlm.nih.gov/pubmed/32065055 http://dx.doi.org/10.1080/22221751.2020.1729069

Ejemplares similares

A novel coronavirus (2019-nCoV) causing pneumonia-associated respiratory syndrome
por: Jiang, Shibo, et al.
Publicado: (2020)

Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein
por: Xia, Shuai, et al.
Publicado: (2020)

Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein
por: Xia, Shuai, et al.
Publicado: (2014)

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
por: Xia, Shuai, et al.
Publicado: (2020)

Patient Perspectives on Anti-spike Monoclonal Antibody Therapy for Mild to Moderate Coronavirus Disease-2019
por: Razonable, Raymund R, et al.
Publicado: (2022)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Potent germline-like monoclonal antibodies: rapid identification of promising candidates for antibody-based antiviral therapy
por: Zhu, Xiaoyi, et al.
Publicado: (2021)

A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike
por: Xia, Shuai, et al.
Publicado: (2019)

The impact of receptor-binding domain natural mutations on antibody recognition of SARS-CoV-2
por: Li, Cheng, et al.
Publicado: (2021)

Identification of Human Single-Domain Antibodies against SARS-CoV-2
por: Wu, Yanling, et al.
Publicado: (2020)

Characterization of novel monoclonal antibodies against MERS-coronavirus spike protein
por: Goo, Junghyun, et al.
Publicado: (2020)

Development of human neutralizing monoclonal antibodies for prevention and therapy of MERS-CoV infections
por: Ying, Tianlei, et al.
Publicado: (2015)

Neutralizing monoclonal antibodies against highly pathogenic coronaviruses
por: Xiang, Rong, et al.
Publicado: (2022)

Anti-Spike Monoclonal Antibody Therapy in Pregnant Women With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
por: Thilagar, Bright P., et al.
Publicado: (2022)

ACE2-targeting monoclonal antibody as potent and broad-spectrum coronavirus blocker
por: Chen, Yuning, et al.
Publicado: (2021)

A highly potent and stable pan-coronavirus fusion inhibitor as a candidate prophylactic and therapeutic for COVID-19 and other coronavirus diseases
por: Zhou, Jie, et al.
Publicado: (2022)

Neutralizing monoclonal antibody in patients with coronavirus disease 2019: an observational study
por: Liao, Xuejiao, et al.
Publicado: (2022)

RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response
por: Liu, Zezhong, et al.
Publicado: (2020)

Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins
por: Zhou, Peng, et al.
Publicado: (2009)

A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
por: Cai, Yanxing, et al.
Publicado: (2021)

The prominent role of a CDR1 somatic hypermutation for convergent IGHV3-53/3-66 antibodies in binding to SARS-CoV-2
por: Tian, Xiaolong, et al.
Publicado: (2022)

Broad-Spectrum Coronavirus Fusion Inhibitors to Combat COVID-19 and Other Emerging Coronavirus Diseases
por: Wang, Xinling, et al.
Publicado: (2020)

Synergistic Effect by Combining a gp120-Binding Protein and a gp41-Binding Antibody to Inactivate HIV-1 Virions and Inhibit HIV-1 Infection
por: Wang, Xinling, et al.
Publicado: (2021)

Pan-coronavirus fusion inhibitors as the hope for today and tomorrow
por: Wang, Xinling, et al.
Publicado: (2021)

A Potent Germline-like Human Monoclonal Antibody Targets a pH-Sensitive Epitope on H7N9 Influenza Hemagglutinin
por: Yu, Fei, et al.
Publicado: (2017)

Monoclonal antibodies constructed from COVID-19 convalescent memory B cells exhibit potent binding activity to MERS-CoV spike S2 subunit and other human coronaviruses
por: Peng, Yuan, et al.
Publicado: (2022)

Potent universal beta-coronavirus therapeutic activity mediated by direct respiratory administration of a Spike S2 domain-specific human neutralizing monoclonal antibody
por: Piepenbrink, Michael S., et al.
Publicado: (2022)

Association of Neutralizing Antispike Monoclonal Antibody Treatment With Coronavirus Disease 2019 Hospitalization and Assessment of the Monoclonal Antibody Screening Score
por: Johnson, Patrick W., et al.
Publicado: (2023)

Adaptive Evolution of the Spike Protein in Coronaviruses
por: Tang, Xiaolu, et al.
Publicado: (2023)

Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Combination Therapy in Patients With Coronavirus Disease 2019 and Primary Antibody Deficiency
por: Pulvirenti, Federica, et al.
Publicado: (2021)

Identification of immunogenic determinants of the spike protein of SARS-like coronavirus
por: Zhou, Peng, et al.
Publicado: (2013)

Effect of Monoclonal Antibody Treatment on Clinical Outcomes in Ambulatory Patients With Coronavirus Disease 2019
por: Anderson, Blake, et al.
Publicado: (2021)

A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies
por: Wang, Chunyan, et al.
Publicado: (2021)

Antigenicity and receptor-binding ability of recombinant SARS coronavirus spike protein
por: Ho, Tin-Yun, et al.
Publicado: (2004)

Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC
por: Du, Lanying, et al.
Publicado: (2013)

Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III
por: Wu, Yanling, et al.
Publicado: (2017)

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
por: Coleman, Christopher M., et al.
Publicado: (2014)

An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus
por: Traggiai, Elisabetta, et al.
Publicado: (2004)

Neutralizing Monoclonal Antibodies for Coronavirus Disease 2019 (COVID-19) in Pregnancy: A Case Series
por: Richley, Michael, et al.
Publicado: (2022)

Outcomes of B-Cell-Depleted Patients With Coronavirus Disease 2019 Treated With Antispike Monoclonal Antibodies
por: Yetmar, Zachary A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nqqv0qpnrk6a4sbgdsugktq8mj